Ma Xiao-Di, Xu Zheng-Li, Huang Xiao-Jun
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation Peking University Beijing China.
Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies Peking University Beijing China.
MedComm (2020). 2025 May 19;6(6):e70206. doi: 10.1002/mco2.70206. eCollection 2025 Jun.
Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) has emerged as a critical treatment for hematological diseases. However, challenges, such as graft rejection and graft-versus-host disease (GVHD), have historically been faced with this procedure. Immune reconstitution (IR) has been shown to have profound effects on posttransplantation complications, such as relapse, infections, and GVHD. Recent advances in non-T-cell depletion protocols including the Beijing protocol and Baltimore protocol have significantly influenced the outcomes of haplo-HSCT by improving IR. Clinical studies and multiomic analyses have revealed that different protocols offer distinct mechanisms for IR patterns and further influence clinical outcomes. However, there is a lack of comprehensive reviews that systematically link the differences in IR between two protocols to their clinical outcomes, which leaves a critical gap in understanding the optimal strategies for IR in haplo-HSCT. This review provides an analysis of IR following haplo-HSCT with different protocols; it compares the clinical outcomes of various protocols, addresses the role of each immune cell subset in influencing outcomes and discusses emerging strategies aimed at improving IR. This review highlights the importance of ongoing research for improving immune reconstitution strategies, ultimately reducing posttransplant complications and offering targeted treatments to improve patient outcomes.
单倍体相合造血干细胞移植(haplo-HSCT)已成为治疗血液系统疾病的关键方法。然而,该方法一直面临着移植物排斥和移植物抗宿主病(GVHD)等挑战。免疫重建(IR)已被证明对移植后并发症,如复发、感染和GVHD有深远影响。包括北京方案和巴尔的摩方案在内的非T细胞清除方案的最新进展,通过改善免疫重建显著影响了haplo-HSCT的结果。临床研究和多组学分析表明,不同的方案为免疫重建模式提供了不同的机制,并进一步影响临床结果。然而,缺乏全面的综述系统地将两种方案之间免疫重建的差异与其临床结果联系起来,这在理解haplo-HSCT中免疫重建的最佳策略方面留下了关键空白。本综述分析了采用不同方案进行haplo-HSCT后的免疫重建;比较了各种方案的临床结果,阐述了每个免疫细胞亚群在影响结果中的作用,并讨论了旨在改善免疫重建的新兴策略。本综述强调了持续研究对于改善免疫重建策略的重要性,最终减少移植后并发症,并提供靶向治疗以改善患者预后。